(CVS | 24 April 2024) AI Stock Analysis & News

Shares of CVS Health Corporation dropped after a gap down in the market, potentially impacting the stock price.

Stock AI’s forecasts:
🔴 -5.0% short-term
🟢 +1.1% long-term

Stock AI’s (CVS) Forecast get (+10.2% Profit)


StockAI’s analysis delivers real-world results. On 14 March 2024, $CVS ($75.6), StockAI predicted a long-term 🔴 sell signal. It was accurate: 1 month later price dropped to $67.9 (🔴-10.2%). Selling CVS on this signal yielded a +10.2% profit 💰💰.

CVS-CVS Health Corporation News


🔴 CVS Health shares gapped down before the market opened on Tuesday, opening at $74.88 instead of closing at $79.56.
🟢 Cantor Fitzgerald reissued their “overweight” rating on CVS Health stock, with a price target of $87.00.
🔴 CVA Family Office LLC increased its position in CVS Health by 8.4% during the 4th quarter.
🟢 Bristlecone Advisors LLC raised its position in CVS Health by 58.4% during the 4th quarter.
🔴 Stolper Co lowered its position in CVS Health by 3.3% during the fourth quarter.
🟢 Norway Savings Bank reduced its position in CVS Health by 0.7% in the fourth quarter.

CVS Health Corporation stock has recently experienced mixed news, with some positive developments such as Cantor Fitzgerald reissuing an “overweight” rating and price target increase, while also facing challenges like a decrease in share price and reduction in position by some institutional investors. Overall, the short-term forecast for CVS stock is a -5.0% decrease, likely influenced by negative news, while the long-term forecast shows a +1.1% increase. Investors should closely monitor any further developments to make informed decisions about their investments in CVS Health.

CVS-CVS Health Corporation Analyst Ratings


In recent analyst ratings for CVS Health Corporation stock, there have been some changes worth noting:

📈 Cantor Fitzgerald reiterated their overweight rating on CVS Health (NYSE:CVS) stock.
📉 Wells Fargo & Company lowered their target price on CVS Health (NYSE:CVS) stock from $83.00 to $76.00.
📉 Leerink Partnrs reduced their Q2 2024 earnings per share estimates for CVS Health (NYSE:CVS) stock.

Sources:
Cantor Fitzgerald
Wells Fargo & Company
Leerink Partnrs

Disclaimer


Investors may consider the AI predictions and news summaries as one factor in their investment decisions alongside their own research and risk tolerance.

Hero Image

Get the same AI-powered insights for any stock you choose. It's easy!